Lundbeck

8 June 2008

UK general physicians can now offer melatonin on prescription to treat older adult patients diagnosed with primary insomnia. Danish drugmaker H Lundbeck's Circadin is the first pharmaceutical-grade licensed melatonin available in the UK for the short-term treatment of primary insomnia in patients aged 55 years or over. The agent is a prolonged-release formulation of synthesized melatonin that is released over several hours in order to provide the body with melatonin at an adequate physiological level during the normal hours of resting.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >






Company Spotlight